Baseline levels of CTX-MMP, TRACP5b, CTX, RANKL, osteocalcin, and PINP were dependent on whether the patients received concomitant BST as reported previously in prostate cancer patients with bone metastatic disease [38–40]. Here, TNFSF11 is linked to prostate carcinoma.